SAN DIEGO (EGMN) - The novel antibody blinatumomab induced high complete remission rates in adults with relapsed B-precursor acute lymphoblastic leukemia in early clinical trials, according to Dr. Max S. Topp.In a phase II study with a dose-finding phase, 9 of 12 patients who received blinatumomab 5 mcg/m² per day for 1 week, followed by a 15-mcg dose on subsequent weeks, had either a complete remission (CR) or a CR with partial hematologic recovery (CRh), Dr. Topp of the University of Würzburg (Germany)...